期刊文献+

宫颈癌中EGFR和FSCN1的表达及其相关性 被引量:4

Expression and correlation of EGFR and FSCN1 in cervical cancer
下载PDF
导出
摘要 目的:探讨宫颈癌中表皮生长因子受体1(EGFR)及Fascin-1(FSCN1)蛋白的表达及其相关性。方法:采用免疫组织化学En Vision法检测120例宫颈癌组织中EGFR及FSCN1蛋白的表达。结果:宫颈癌组织中EGFR蛋白阳性率为89.2%(107/120),FSCN1蛋白阳性率为99.2%(119/120),其中强阳性率为88.3%(106/120)。EGFR阳性表达与FSCN1强阳性表达呈显著正相关(P<0.01)。结论:宫颈癌中EGFR可能参与正性调控FSCN1表达。 Objective: To explore the expression of EGFR and FSCN1 protein in cervical cancer and its correlation. Methods: The expression of EGFR and FSCN1 in 120 cases of cervical cancer was evaluated with immunohistochemical technique, EnVision method. Results: EGFR protein expression rates in cervical cancer was 89.2% (107/120). FSCN1 protein positive rate in cervical cancer was 99.2% (119/120), in which strong positive rate was 88.3% (106/120). EGFR positive expression was significantly positive correlation with FSCN1 strong positive expression (P〈0.01). Conelusion: EGFR may participate in positive regulation FSCNI expres- sion in cervical cancer.
出处 《温州医科大学学报》 CAS 2016年第1期72-74,共3页 Journal of Wenzhou Medical University
基金 金华市科技计划重点项目(2012-3-021) 金华市科技计划项目(2013-3-097) 浙江省医药卫生科技计划项目(2012KYB230)
关键词 表皮生长因子受体1 FASCIN-1 宫颈肿瘤 免疫组织化学 EGFR FSCN1 cervical neoplasms immunohistochemistry
  • 相关文献

参考文献5

二级参考文献47

  • 1唐礼榕,张志毅.HPV-DNA检测在宫颈病变诊断中的价值[J].中国癌症杂志,2006,16(3):217-219. 被引量:33
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:278
  • 3薛丽燕,滕梁红,邹霜梅,任立群,郑闪,罗巍,毕蕊,吕宁.膜联蛋白Ⅰ在多种癌组织中的表达[J].中华肿瘤杂志,2007,29(6):444-448. 被引量:10
  • 4曾瑄,王鹏,武莎斐,高洁,梁智勇,刘彤华.结直肠癌EGFR和HER2蛋白表达及其基因拷贝数分析[J].中华病理学杂志,2007,36(7):447-452. 被引量:8
  • 5Reis-Filho JS,Simpson PT,Martins A,et al.Distribution of p63,cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.Virchows Arch,2003,443:122-132.
  • 6Swierczynski SL,Maitra A,Abraham SC,et al.Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays.Hum Pathol,2004,35:357-366.
  • 7Grothey A,Hashizume R,Sahin AA,et al.Fascin,an actinbundling protein associated with cell motility,is upregulated in hormone receptor negative breast cancer.Br J Cancer,2000,83:870-873.
  • 8Hu W,McCrea PD,Deavers M,et al.Increased expression of fascin,mollify associated protein,in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.Clin Exp Metastasis,2000,18:83-88.
  • 9Pelosi G,Pastorino U,Pasini F,et al.Independent prognostic value of fascin immunoreactivity in stage Ⅰ non small cell lung cancer.Br J Cancer,2003,88:537-547.
  • 10Hashimoto Y,lto T,Inoue H,et al.Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma.Clin Cancer Res,2005,11:2597-2605.

共引文献59

同被引文献35

  • 1于馨,曹军英,金壮,蒋南,高越,里子彧.乳腺浸润性导管癌超声表现与雌激素受体、孕激素受体、人表皮生长因子受体-2、Ki-67表达相关性分析[J].临床军医杂志,2022,50(7):666-669. 被引量:2
  • 2热依兰木·买赛地,沙静,韩莉莉.EGFR在宫颈癌组织中的表达及意义研究[J].兵团医学,2022(2):34-36. 被引量:1
  • 3MORICE P, LEARY A, CREUTZBERG C, et al. Endometrialcancer[J]. Lancet, 2016, 387(10023): 1094-1108.
  • 4FURRER D, SANSCHAGRIN F, JACOB S, et al. Advantagesand disadvantages of technologies for HER2 testing inbreast cancer specimens[J]. Am J Clin Pathol, 2015, 144(5):686-703.
  • 5SUBRAMANIAM D, HE A R, HWANG J, et al. Irreversiblemultitargeted ErbB family inhibitors for therapy of lung andbreast cancer[J]. Curr Cancer Drug Targets, 2015, 14(9):775-793.
  • 6WU J, ZHAO S, ZHANG J, et al. Over-expression of Survivinis a factor responsible for differential responses ofovarian cancer cells to S-allylmercaptocysteine (SAMC)[J].Exp Mol Pathol, 2016, 100(2): 294-302.
  • 7AKSOY R T, TURAN A T, BORAN N, et al. Lack of relationof Survivin gene expression with survival and surgicalprognostic factors in endometrial carcinoma patients[J].Asian Pac J Cancer Prev, 2014, 15(16): 6905-6910.
  • 8VANDERSTRAETEN A, EVERAERT T, VAN BREE R,et al. In vitro validation of Survivin as target tumor-associatedantigen for immunotherapy in uterine cancer[J]. J Immunother,2015, 38(6): 239-249.
  • 9TAKEDA M, NAKAGAWA K. Role of EGFR monoclonalantibodies in the management of non-small cell lung cancer[J]. Curr Cancer Drug Targets, 2015, 15(9): 792-802.
  • 10LIVASY C A, READING F C, MOORE D T, et al. EGFRexpression and HER2/neu overexpression/amplification inendometrial carcinosarcoma[J]. Gynecol Oncol, 2006, 100(1): 101-106.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部